In the last trading session, 4.06 million Gamida Cell Ltd (NASDAQ:GMDA) shares changed hands as the company’s beta touched 1.32. With the company’s per share price at $0.31 changed hands at -$0.01 or -4.00% during last session, the market valuation stood at $40.76M. GMDA’s last price was a discount, traded about -709.68% off its 52-week high of $2.51. The share price had its 52-week low at $0.26, which suggests the last value was 16.13% up since then. When we look at Gamida Cell Ltd’s average trading volume, we note the 10-day average is 3.13 million shares, with the 3-month average coming to 1.14 million.
Analysts gave the Gamida Cell Ltd (GMDA) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended GMDA as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Gamida Cell Ltd’s EPS for the current quarter is expected to be -$0.15.
Gamida Cell Ltd (NASDAQ:GMDA) trade information
Instantly GMDA was in red as seen at the end of in last trading. With action -48.45%, the performance over the past five days has been red. The drop to weekly highs of 0.6282 on Friday, 11/17/23 subtracted -4.00% to the stock’s daily price. The company’s shares are showing year-to-date downside of -76.18%, with the 5-day performance at -48.45% in the red. However, in the 30-day time frame, Gamida Cell Ltd (NASDAQ:GMDA) is -63.68% down. Looking at the short shares, we see there were 7.35 million shares sold at short interest cover period of 10.22 days.
The consensus price target for the stock as assigned by Wall Street analysts is $4.00, meaning bulls need an upside of 92.25% from its current market value. According to analyst projections, GMDA’s forecast low is $2.00 with $6.00 as the target high. To hit the forecast high, the stock’s price needs a -1835.48% plunge from its current level, while the stock would need to soar -545.16% for it to hit the projected low.
Gamida Cell Ltd (GMDA) estimates and forecasts
Data shows that the Gamida Cell Ltd share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -85.01% over the past 6 months, a 46.77% in annual growth rate that is considerably higher than the industry average of 14.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Gamida Cell Ltd will rise 50.00%, while the growth in revenue is estimated to hit 51.90% for the next quarter.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of $1.06 million. 2 analysts are of the opinion that Gamida Cell Ltd’s revenue for the quarter ending Mar 2024 will be $3.22 million.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -9.78%. The 2023 estimates are for Gamida Cell Ltd earnings to increase by 37.90%.
Gamida Cell Ltd is expected to release its next quarterly earnings report on November 14.
Gamida Cell Ltd (NASDAQ:GMDA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 20.74% of Gamida Cell Ltd shares while 30.76% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 38.81%. There are 30.76% institutions holding the Gamida Cell Ltd stock share, with FMR, LLC the top institutional holder. As of Jun 29, 2023, the company held 7.04% of the shares, roughly 8.55 million GMDA shares worth $16.5 million.
Meitav Investment House Ltd. holds the second largest percentage of outstanding shares, with 3.01% or 3.66 million shares worth $7.05 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Aug 30, 2023 were Variable Insurance Products Fund-Growth Portfolio and Fidelity Capital Appreciation Fund. With 2.21 million shares estimated at $2.61 million under it, the former controlled 1.82% of total outstanding shares. On the other hand, Fidelity Capital Appreciation Fund held about 1.78% of the shares, roughly 2.17 million shares worth around $3.1 million.